PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

200002043-8
12/6/00

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/00	A2	(11) International Publication Number: WO 99/20260
		(43) International Publication Date: 29 April 1999 (29.04.99)

(21) International Application Number: PCT/GB98/03122

(22) International Filing Date: 19 October 1998 (19.10.98)

(30) Priority Data:

9722026.3	17 October 1997 (17.10.97)	GB
60/067,819	5 December 1997 (05.12.97)	US
9810855.8	20 May 1998 (20.05.98)	GB
60/094,902	31 July 1998 (31.07.98)	US

(71) Applicant *(for all designated States except US)*: EUROGENE LIMITED [GB/GB]; Marquis House, 67/68 Jermyn Street, London SW1Y 6NY (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: MONTGOMERY, Hugh, Edward [GB/GB]; University College London Medical School, Dept. of Medicine, Centre for Cardiovascular Genetics, Rayne Institute, 5 University Street, London WC1E 6JJ (GB). MARTIN, John, Francis [GB/GB]; Saint Martin's House, Tottenham Court Road, London W1P 9LN (GB). ERUSALIMSKY, Jorge, Daniel [GB/GB]; University College London, The Wolfson Institute for Biomedical Research, Rayne Institute, Ground floor, 5 University Street, London WC1E 6JJ (GB).

(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: THE USE OF INHIBITORS OF THE RENIN–ANGIOTENSIN SYSTEM

(57) Abstract

It has been found that an inhibitor of the renin–angiotensin system is useful for the treatment or prevention of a condition associated with hypoxia or impaired metabolic function or efficiency. In particular, it may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and is thus useful in treatment of the symptoms and signs of ageing. It may also be used to enhance function in healthy subjects.